| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Chronic graft-versus-host disease (GVHD) is the main cause of late death and morbidity after allogeneic stem cell transplantation (SCT). Fibrosis constitutes the end stage of the inflammatory process in chronic GVHD leading to major morbidity. Recently, segregated-nucleus-containing atypical monocytes (SatM) that involved in lung fibrosis has been identified. Ly6clow monocyte, Ly6c+ monocyte and SatM increased in BALF of allogeneic recipient. In the sclerodermatous chronic GVHD model, SatM increased in ear of allogeneic group. From these results, we hypothesized that SatM may cause the fibrosis of chronic GVHD. To demonstrate that SatM causes the fibrosis of chronic GVHD, we established GVHD model with SatM deficiency mouse (Cebpb-/- mouse). Recipient of SatM deficiency mouse showed exacerbated GVHD, suggesting that Cebpb-/- donor cells have decreased regulatory function.
|
